Par Drugs and Chemicals Ltd (PAR) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Par Drugs and Chemicals Ltd on NSE and BSE, with an AI summary of each filing.
Par Drugs And Chemicals Limited has informed the Exchange regarding 'Outcome of Board Meeting dated 29.10.2026'.
Outcome · 29 Oct 2026, 10:37 pm
Par Drugs and Chemicals Reports Q2 FY27 Results Par Drugs and Chemicals reported revenue from operations of ₹2,743.19 lakhs for the quarter ended 30th Sep'26, down 4.28% YoY from ₹2,865.89 lakhs and 12.30% QoQ from ₹3,128.05 lakhs. Net profit declined 36.36% YoY to ₹262.80 lakhs compared to ₹412.96 lakhs in Q2 FY26 and ₹471.27 lakhs in Q1 FY27. Quarterly basic and diluted EPS stood at ₹2.14 versus ₹3.36 in the previous year. For the half-year ended 30th Sep'26, revenue rose 7.33% YoY to ₹5,871.24 lakhs, while net profit dropped slightly to ₹734.07 lakhs.
Par Drugs And Chemicals Limited has informed the Exchange regarding Outcome of Board Meeting held on October 29, 2026.
Outcome · 29 Oct 2026, 10:35 pm
Par Drugs & Chemicals Reports Q2 FY27 Financial Results Par Drugs and Chemicals approved its standalone financial results for the quarter ended 30th Sep'26. Revenue from operations reached Rs 2,743.19 lakhs, down 12.30% QoQ from Rs 3,128.05 lakhs in Jun'26 and 4.28% YoY from Rs 2,865.89 lakhs in Sep'25. Net profit dropped 44.23% QoQ and 36.36% YoY to Rs 262.80 lakhs, yielding an EPS of Rs 2.14 compared to Rs 3.83 in Jun'26 and Rs 3.36 in Sep'25. For H1 ended 30th Sep'26, revenue stood at Rs 5,871.24 lakhs with net profit of Rs 734.07 lakhs.
Par Drugs And Chemicals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 29 Oct 2026, 10:31 pm
Par Drugs and Chemicals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakh) ■ Revenue: 2,743 (-4.3% YoY | -12.3% QoQ) ■ EBITDA: 450 (-25.8% YoY | -29.4% QoQ) ■ EBITDA Margin (%): 16.4 (-475 bps YoY | -398 bps QoQ) ■ PAT: 263 (-36.4% YoY | -44.2% QoQ) ■ EPS (INR): 2.14 (-36.3% YoY | -44.1% QoQ)
PAR DRUGS AND CHEMICALS LIMITED has informed the Exchange about Board Meeting to be held on 29-Oct-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Other business.
Intimation · 29 Oct 2026, 5:30 am
Par Drugs and Chemicals to Consider Half-Yearly Results on 29th Oct'26 Par Drugs and Chemicals Limited has scheduled a meeting of its Board of Directors on 29th Oct'26. The board will convene primarily to consider and approve the company's half-yearly unaudited financial results for the period ended Sep'26, alongside other general corporate business matters.
To consider and approve the financial results for the period ended September 30, 2026 and other business matters
Intimation · 29 Oct 2026, 5:30 am
Par Drugs and Chemicals Schedules Board Meeting for Q2 FY27 Results Par Drugs and Chemicals Limited has scheduled a meeting of its Board of Directors on 29th Oct'26 via video conferencing. Key agenda items include considering and approving the Unaudited Standalone Financial Results along with the Limited Review Report for the quarter and half-year ended 30th Sep'26. Additionally, the board will review the investor grievance report, SEBI SCORES platform status, corporate governance report for the period, and finalize related newspaper advertisement publications.
Par Drugs And Chemicals Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 26, 2026. Further, the company has informed the Exchange regarding voting results.
Annual General Meeting · 27 Sept 2026, 6:50 pm
Par Drugs And Chemicals Limited has informed the Exchange regarding 'Proceeding of AGM dated 26.09.2026'.
Annual General Meeting · 26 Sept 2026, 8:27 pm
Par Drugs And Chemicals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 26, 2026
Annual General Meeting · 26 Sept 2026, 8:24 pm
Par Drugs And Chemicals Limited has informed the Exchange regarding 'Regulation 36 (1)(b)'.
Others (Uncategorized) · 01 Sept 2026, 11:13 pm
Par Drugs Announces 27th AGM and FY26 Annual Report Details Par Drugs and Chemicals has scheduled its 27th Annual General Meeting for 11:00 AM on Sat, 26th Sep'26. The company will distribute the FY 2025-26 Annual Report and AGM notice electronically on 03rd Sep'26 to shareholders registered as of the cut-off date, 21st Aug'26. Shareholders without a registered email will be provided a web link to access the documents, which will also be available on the company's website. The meeting will be held at Hotel Tara Suns, Vadodara, Gujarat.
Par Drugs And Chemicals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 26, 2026
Annual General Meeting · 22 Aug 2026, 11:46 pm
Par Drugs And Chemicals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 22, 2026.
Outcome · 22 Aug 2026, 11:36 pm
Par Drugs And Chemicals Limited has informed the Exchange regarding Appointment of Ms SIDDHPURA & CO, Internal Auditor as Internal auditor of the company w.e.f. April 01, 2026.
Change in Management · 22 Aug 2026, 11:34 pm
Par Drugs And Chemicals Limited has informed the Exchange regarding 'Outcome of Board Meeting dated 22.08.2026'.
Outcome · 22 Aug 2026, 11:23 pm
PAR DRUGS AND CHEMICALS LIMITED has informed the Exchange about Board Meeting to be held on 22-Aug-2026 to consider Other business.
Intimation · 13 Aug 2026, 8:34 pm
Par Drugs & Chemicals Schedules Board Meeting for Aug'26 Par Drugs and Chemicals Ltd. has scheduled a Board of Directors meeting for 22-Aug'26. The agenda is to consider unspecified "Other business," indicating potential corporate actions or strategic discussions that have not yet been disclosed to the market.
To consider other business matters
Others (Uncategorized) · 13 Aug 2026, 8:33 pm
Par Drugs Board Meeting to Discuss Director Remuneration Increase and AGM Par Drugs and Chemicals has scheduled a Board of Directors meeting for 22nd Aug'26. Key agenda items include approving an increase in remuneration for Chairman & MD Falgun V. Savani and Director & CEO Jignesh V. Savani. The board will also decide the date and details for its 27th AGM, approve the Directors' Report for the financial year ended 31st Mar'26, and appoint statutory, internal, and cost auditors for FY 2026-27. Other matters cover fixing remuneration for an Independent Director and approving audit reports.
Par Drugs And Chemicals Limited has informed the Exchange regarding 'Outcome of Board Meeting dated 08.08.2026'.
Outcome · 08 Aug 2026, 10:59 pm
Par Drugs Q1FY27: Net Profit Surges 41.6% YoY on Strong Revenue Growth Par Drugs and Chemicals reported a strong Q1FY27 performance with standalone net profit rising 41.6% YoY to ₹4.71 Cr. Total revenue grew 15.5% YoY to ₹32.22 Cr. On a QoQ basis, revenue increased by 61.4% and net profit surged 452.1% from ₹85.36 lakhs in Q4FY26. The board also approved the sale of a motor vehicle for ₹3.60 lakhs and the purchase of new vehicles totaling ₹72.35 lakhs for directors. Additionally, the company appointed NEO Alternative Asset Managers as its portfolio manager.
Par Drugs And Chemicals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 08, 2026.
Outcome · 08 Aug 2026, 10:56 pm
Par Drugs Q1FY27 Net Profit Rises 42% YoY Par Drugs reported strong Q1FY27 results with net profit at ₹471.27 lakhs, up 41.6% YoY and 452.1% QoQ. Total revenue grew to ₹3,221.58 lakhs, a 15.5% YoY and 61.3% QoQ increase. Profit before tax (PBT) stood at ₹633.01 lakhs, rising 41.4% YoY. The Board also approved appointing a portfolio manager and purchasing new vehicles for directors worth a combined ₹72.35 lakhs. Basic EPS for the quarter was ₹3.83, compared to ₹2.70 in Q1FY26 and ₹0.69 in Q4FY26.
Par Drugs And Chemicals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
Outcome · 08 Aug 2026, 10:53 pm
Par Drugs and Chemicals Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakh) ■ Revenue: 3,128 (+20.1% YoY | +59.5% QoQ) ■ EBITDA: 638 (+79.2% YoY | +342.5% QoQ) ■ EBITDA Margin (%): 20.4 (+673 bps YoY | +1304 bps QoQ) ■ PAT: 471 (+41.6% YoY | +452.1% QoQ) ■ EPS (INR): 3.83 (+41.9% YoY | +455.1% QoQ)
PAR DRUGS AND CHEMICALS LIMITED has informed the Exchange about Board Meeting to be held on 08-Aug-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended June 2026 and Other business.
Intimation · 08 Aug 2026, 5:30 am
Par Drugs & Chemicals Board to Review Q1 FY27 Results on 08-Aug'26 Par Drugs and Chemicals Ltd. has scheduled a Board of Directors meeting for 08-Aug'26. The primary agenda is to consider and approve the company's unaudited financial results for the first quarter ending 30-Jun'26. Other business matters will also be discussed during the meeting.
To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters
Financial Result · 31 Jul 2026, 10:57 pm
Par Drugs Announces Board Meeting for Q1 FY27 Results Par Drugs and Chemicals Ltd has scheduled a Board of Directors meeting on 8th Aug'26 at 3:30 P.M. to consider and approve the unaudited standalone financial results for the quarter ending 30th Jun'26. The agenda also includes reviewing the limited review report from the statutory auditor and discussing other corporate governance matters. This meeting will be conducted via video conferencing.